

FIRST U.S. CLINICAL PILOT FOR XV LVAS AT ST. JOSEPH HOSPITAL IN ORANGE COUNTY, CALIFORNIA

- 4DMedical to commence the first U.S. clinical pilot of its XV Lung Ventilation Analysis Software (XV LVAS[™]) offering at St. Joseph Hospital located in Orange County, California
 - XV LVAS will be used to assist in screening for a variety of lung conditions, including COVID-19
 - The clinical pilot follows on from XV LVAS receiving FDA 510(k) clearance in May 2020 and Class 1 approval from the Australian Therapeutic Goods Administration (TGA) in September 2020
 - XV LVAS uses the Company's proprietary XV Technology[™], which converts sequences of X-ray images into four-dimensional quantitative data by using mathematical models and algorithms
 - XV LVAS is 4DMedical's first Software-as-a-Service (SaaS) offering and can provide immediate benefits to physicians and patients worldwide, including aiding in the diagnosis of respiratory diseases earlier and with more sensitivity while using existing hospital and clinic equipment
-

27 January 2021: 4DMedical Limited (ASX: 4DX, "4DMedical" or the "Company"), a medical technology company focused on commercialising its patented respiratory imaging platform, is pleased to announce the first clinical pilot for XV Lung Ventilation Analysis Software ("XV LVAS") will be conducted at St. Joseph Hospital located in Orange County, California, U.S.

St. Joseph Hospital is one of 51 hospitals owned by Providence Health & Services, the third largest not-for-profit health system in the U.S., which offers nearly every medical speciality and sub-speciality to patients.

The clinical pilot represents the first clinical usage of XV LVAS on patients in the U.S. and will be used to aid hospital physicians to screen for a variety of lung conditions, including asthma, emphysema, pulmonary fibrosis, lung cancer and COVID-19. As part of the pilot, St. Joseph Hospital will conduct a full review of 4DMedical's end-to-end solution over the coming months.

The clinical pilot signifies the commencement of the Company's commercialisation phase in the U.S. as patients start to receive XV LVAS scans as part of standard clinical practice, in both inpatient and outpatient settings.

Clinical pilots will form an important part of the commercial rollout of XV LVAS in the U.S., allowing hospitals and medical institutions to implement and trial 4DMedical's end-to-end solution ahead of potential commercial integration.

The clinical pilot with St. Joseph Hospital follows on from XV LVAS receiving FDA 510(k) clearance in May 2020, as well as Class 1 regulatory approval from the Australian Therapeutic Goods Administration (TGA) in September 2020, enabling 4DMedical to sell and market XV LVAS in the U.S. and Australia respectively. As previously announced to the ASX on 18 December 2020, the first commercial scans have already been conducted in Australia.

Supported by more than 15 years of development in Australia and using the Company's XV Technology platform, XV LVAS improves the capacity of physicians to diagnose and treat patients with respiratory diseases more efficiently, by providing objective measurements of regional lung motion and air flow.

Importantly, XV LVAS has been validated to monitor Acute Respiratory Distress Syndrome (ARDS), a respiratory condition caused by COVID-19, as part of its FDA 510(k) clearance and has the potential to be used to accelerate therapy research and assess the effectiveness of potential treatments. With over 20% of the global COVID-19 cases currently located in the U.S., 4DMedical and St. Joseph Hospital will work together to provide relevant assessment scans to current and past COVID-19 patients.

Andreas Fouras, Founder & CEO of 4DMedical said:

"We are extremely pleased to announce the commencement of the clinical pilot in collaboration with St. Joseph Hospital as it signifies the commencement of our commercialisation phase in the U.S. We believe that XV LVAS is a unique tool that can assist physicians in diagnosing and managing patients with various lung diseases, including COVID-19, as it provides physicians with a unique picture of how air moves in the lungs.

"We have been extremely pleased with the feedback received from leading hospitals and clinics in the U.S., our priority market, and remain focused on continuing to progress the commercial rollout of XV LVAS."

ENDS

Authorised by the 4DMedical Board of Directors.

Contacts:

<i>Corporate</i>	<i>Investor</i>	<i>Media</i>
Charlene Stahr	Simon Hinsley	Matthew Wright
Company Secretary	+ 61 401 809 653	+ 61 451 896 420
companysecretary@4dmedical.com	shinsley@4dmedical.com	matt@nwrcommunications.com.au

About St. Joseph Hospital:

Founded in 1929, St. Joseph Hospital in Orange, California is a nationally recognized, 463-bed, not-for-profit Catholic hospital dedicated to extending the healing ministry of Jesus in the tradition of the Sisters of St. Joseph of Orange. Fully accredited by The Joint Commission and designated as a Magnet hospital for nursing excellence, St. Joseph Hospital's reputation for clinical excellence and compassionate, family-centered care draws patients from all over the United States. This is one reason why St. Joseph Hospital was named one of the top hospitals in the Los Angeles/Orange County area by U.S. News & World Report.

With a highly recognized 1,000-member medical staff and more than 3,100 support staff, St. Joseph Hospital is home to more than 75 specialty programs, including The Center for Cancer Prevention and Treatment, the Heart and Vascular Center and a nationally acclaimed Orthopedics program that has been ranked among the top 50 in the nation by U.S. News & World Report. Equally important is St. Joseph Hospital's dedication to caring for the medically underserved through health education programs, a free-standing medical and dental clinic, and mobile health vans. St. Joseph Hospital depends on philanthropic support from the community to carry out its mission. These efforts are coordinated through the St. Joseph Hospital Foundation.

About 4DMedical:

Based in Melbourne, Australia and Los Angeles, USA, 4DMedical (formerly 4Dx) was founded in 2012 and is listed on the Australian Securities Exchange (ASX: 4DX).

4DMedical is a medical technology company aiming to deliver the global gold standard in respiratory diagnostics for all lung disorders including: coronavirus, asthma, chronic obstructive pulmonary disease (COPD), cystic fibrosis and cancer.

The unique 4DMedical technology accurately and quickly scans lung function as the patient breathes, to assist in providing sensitive, early diagnosis, and to monitor changes over time. Our Software-as-a-Service

(SaaS) scans deliver much more complete results, showing even subtle variations in lung function down to the finest details, using lower levels of radiation than traditional methods.

Respiratory diagnosis is a US\$31 billion per annum global industry. Through its technology 4DMedical provides clinicians with greater insights into diseases of the lung. 4DMedical is focused on providing better information to doctors and patients about lung function. Better information means better decisions, and better outcomes.